Publication Title

J Immunother Cancer

Document Type

Article

Publication Date

12-4-2018

Keywords

Biomarkers; Cancer immunotherapy; Checkpoint inhibitor; PD-1/PD-L1

Abstract

Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomarker development and utilization, the Society for Immunotherapy of Cancer (SITC) convened a workshop, "Immuno-Oncology Biomarkers: State of the Art," on May 16-17, 2018. Topics discussed included challenges in handling biospecimens, identification and validation of new biomarkers, data sharing, and collaborating across disciplines to advance biomarker development. Panel discussions followed session presentations to help foster participant conversation and discuss future projects and collaborations. The results of the Workshop include the development of new initiatives for the SITC Biomarkers Committee.

Clinical Institute

Cancer

Specialty

Oncology

Specialty

Earle A. Chiles Research Institute

Included in

Oncology Commons

Share

COinS